Cutia Therapeutics (2487) Stock Statistics & Valuation Metrics

Cutia Therapeutics has a market cap or net worth of HK$3.01B. The enterprise value is HK$2.71B.

Cutia Therapeutics has 320,359,100 shares outstanding. The number of shares has decreased by -2.65% in one year.

Cutia Therapeutics’s return on equity (ROE) is -0.45 and return on invested capital (ROIC) is -35.13%.

The current PE Ratio of Cutia Therapeutics is -4.50. Cutia Therapeutics’s PEG ratio is -0.68.

In the last 12 months, Cutia Therapeutics had revenue of 279.62M and earned -433.81M in profits. Earnings per share was -1.41.

In the last 12 months, operating cash flow was -246.16M and capital expenditures -9.75M, giving a free cash flow of -255.91M billion.

Cutia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Cutia Therapeutics upcoming earnings date is Aug 27, 2025, Before Open (Confirmed).

Cutia Therapeutics as a current ratio of 3.36, with Debt / Equity ratio of 32.93%

In the past 12 months, Cutia Therapeutics has paid 0.00 in taxes.

Cutia Therapeutics EV to EBITDA ratio is -4.38, with an EV/FCF ratio of 0.00.

Cutia Therapeutics has HK$876.15M in cash and marketable securities with ¥320.94M in debt, giving a net cash position of -HK$555.22M billion.

Gross margin is 51.31%, with operating margin of -162.78%, and net profit margin of -155.15%.

The average price target for Cutia Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―